ArticleVaccines2019
First-In-Human Trials of GamTBvac, a Recombinant Subunit Tuberculosis Vaccine Candidate: Safety and Immunogenicity Assessment.
Article in Vaccines, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 42 citations in OpenAlex.
- Design of a multi-epitope vaccine against Mycobacterium tuberculosis using reverse vaccinology and immunoreactive peptides.Genomics & informatics · 2026Article
- HowVaccines · 2026Review
- Recent Characterization of Key Proteins to Combat Tuberculosis.Advances in experimental medicine and biology · 2026Review
- Review
- Tuberculosis vaccines and therapeutic drug: challenges and future directions.Molecular biomedicine · 2025Review
- BCG and beyond: unlocking new frontiers in TB vaccine development.Frontiers in immunology · 2025Review
- Immunoinformatics and structural aided approach to develop multi-epitope based subunit vaccine against Mycobacterium tuberculosis.Scientific reports · 2024Article
- Tuberculosis Vaccines and T Cell Immune Memory.Vaccines · 2024Review
- Advances in the development of new vaccines for tuberculosis and Brazil's role in the effort forward the end TB strategy.Memorias do Instituto Oswaldo Cruz · 2024Article
- Review
- ESAT-6 a Major Virulence Factor ofBiomolecules · 2023Review
- Advances in protein subunit vaccines against tuberculosis.Frontiers in immunology · 2023Review
- Bridging the gaps to overcome major hurdles in the development of next-generation tuberculosis vaccines.Frontiers in immunology · 2023Review
- Recent advance in the development of tuberculosis vaccines in clinical trials and virus-like particle-based vaccine candidates.Frontiers in immunology · 2023Review
- Article
- Advance in strategies to build efficient vaccines against tuberculosis.Frontiers in veterinary science · 2022Review
- It Takes a Village: The Multifaceted Immune Response toFrontiers in immunology · 2022Review
- Structure based design of effective HtpG-derived vaccine antigens againstFrontiers in molecular biosciences · 2022Article
- CFP10-loaded PLGA nanoparticles as a booster vaccine confer protective immunity againstBioImpacts : BI · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis is known to be the biggest global health problem, causing the most deaths by a single infectious agent. Vaccine-development efforts are extremely important. This paper represents the results of the first-in-human trial of recombinant subunit tuberculosis vaccine GamTBvac in a Phase I study. GamTBvac is a new BCG booster candidate vaccine containing dextran-binding domain modified Ag85a and ESAT6-CFP10 MTB antigens and CpG ODN adjuvant, formulated with dextrans. Safety and immunogenicity of GamTBvac were estimated in an open-label clinical trial on 60
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.